Aim—To assess the value of immunohistochemistry in discriminating between BRCA1 associated and non-BRCA1 associated breast tumours.
Methods—Four commercially available anti-BRCA1 antibodies were used on 45 paraffin wax embedded tumoral samples from patients with (seven of 45) and without (38 of 45) BRCA1 germline mutations. In all patients, the BRCA1 gene had been studied previously by means of the protein truncation test (PTT), conformational sensitive gel electrophoresis (CSGE), and direct sequencing of genomic DNA. Immunohistochemistry was carried out using the standard avidin–biotin immunoperoxidase method. Antigen retrieval was carried out by means of microwave pretreatment or autoclaving. The antibody panel used comprised D-20 (1/500), I-20 (1/100), K-18 (1/100), and MS110 (Ab-1; 1/50).
Results—No immunohistochemical differences in BRCA1 protein expression were found between cases with and without BRCA1 germline mutations. All positive cases showed predominantly cytoplasmic staining, in both tumoral and non-tumoral cells, with the polyclonal antibodies D-20, I-20, and K-18. After heating pretreatment both nuclear and cytoplasmic staining were found in tumoral and non-tumoral cells with the I-20 antibody. Only the monoclonal antibody MS110 showed a predominantly nuclear staining after microwave oven treatment.
Conclusions—Commercially available BRCA1 antibodies lack the specificity required to identify the BRCA1 protein and thus are not useful for establishing differences between familial and sporadic breast tumours, or between BRCA1 associated and non-BRCA1 associated breast tumours.
- breast carcinoma
- immunohistochemical study
Statistics from Altmetric.com
BRCA1 is a putative tumour suppressor gene1, 2 linked to breast cancer in families with dominant inheritance of the disease.3 Many tumours with germline BRCA1 mutations display loss of heterozygosity (LOH)4 at this locus, with loss of the wild-type BRCA1 allele, indicating a role for BRCA1 as a tumour suppressor gene.
BRCA1 is a large gene with a coding region of 5.5 kb, expanded in 24 exons, and a total mRNA size of approximately 80 kb, which is probably regulated by steroid hormones, oestrogen and progesterone.5, 6 The protein has a RING finger domain at its N-terminus3 and a BRCT motif at its C-terminus,7 which functions as a transactivator.8, 9
The function of the BRCA1 protein is not fully elucidated but it probably plays an important role in DNA repair, apoptosis, or cell cycle arrest, interacting with p53 and RAD51 in response to DNA damage.10–13
There is much controversy with regard to the importance and localisation of BRCA1 protein expression. Chen et al reported that the BRCA1 protein is found in the nuclei of normal epithelial cells, but is aberrantly located in the cytoplasm of malignant mammary cells.14 In contrast, Scully et al found the BRCA1 protein in the nuclei of both normal and malignant cells.15 Jensen et al reported that BRCA1 is located in the cytoplasm and the cell membrane,16 whereas Coene et al proposed that it is located in cytoplasmic tube-like invaginations in the nucleus.17 These contradictory results on the location of the BRCA1 protein could result from differences in the specificity of the antibodies used, the different fixation methods used, and the presence of splice variant isoforms of the BRCA1 protein in tumours.
Immunohistochemical studies on formalin fixed, paraffin wax embedded tumours have demonstrated a loss or reduction of protein expression not only in BRCA1 associated breast carcinomas but also in non-BRCA1 associated familial and sporadic breast carcinomas.18–20
Although the BRCA1 gene is not mutated in sporadic breast carcinomas,3 the loss or reduction of BRCA1 protein expression (as detected by immunohistochemistry)20 and the high frequency of LOH21, 22 indicate that the BRCA1 gene probably features in the genesis of sporadic breast cancer through a mechanism other than mutation.
In our study, we evaluate from a practical point of view the applicability and value of four different commercially available anti-BRCA1 antibodies (polyclonal D-20, I-20, and K-18 and monoclonal MS110) to discriminate between BRCA1 associated and non-BRCA1 associated tumours. We performed an immunohistochemical study on formalin fixed, paraffin wax embedded tumour samples from 45 patients with sporadic and inherited breast cancer, in whom germline mutations of the BRCA1 gene had been studied previously by means of the protein truncation test (PTT), conformational sensitive gel electrophoresis (CSGE), and direct sequencing of genomic DNA.
In total, 45 patients with both sporadic (n = 22) and familial (n = 23) breast cancer were selected. Familial cases had been stratified previously into high and low risk susceptibility groups according to the criteria of Hartmann et al.23 Clinicopathological data were available in all cases (table 1). All tumours were histologically classified according to the WHO criteria24 and were graded according to the Nottingham modification25 of Bloom and Richardson.
A complete gene study in search of BRCA1 germline mutations had been carried out previously by means of PTT, CSGE, and direct sequencing of genomic DNA.
The antibody panel used comprised the polyclonal D-20, I-20, and K18 antibodies from Santa Cruz Biotechnologies (Santa Cruz, California, USA) and the monoclonal MS110 (Ab-1) antibody from Oncogene Research Products (Cambridge, Massachusetts, USA).
Immunohistochemistry was performed on formalin fixed, paraffin wax embedded samples using the standard avidin–biotin immunoperoxidase method. Two different methods were used for antigen retrieval: autoclaving in 0.01 M sodium citrate at 121°C, 15 pounds/square inch for 30 minutes (for the polyclonal antibodies) and heating in a microwave oven at 500 W for 20 minutes in citrate buffer (for the monoclonal antibody). Slides were then incubated with the primary antibodies D-20 (1/500), I-20 (1/100), K18 (1/100), and MS110 (Ab-1; 1/50) and diluted with phosphate buffered saline (PBS) containing 0.5% Triton-X100 (vol/vol). Fixed, paraffin wax embedded myometrium served as a positive control, whereas similarly treated spleen tissue served as a negative control for the polyclonal antibodies, according to Jarvis and colleagues26; the Ab-1 antibody was probed in normal skin and the staining of the basal epithelial cells served as a positive control. The negative control in this case was obtained by omitting the antibody.
Tumours with cytoplasmic and/or nuclear staining were considered positive. The proportion of stained cells was scored as follows: 0 (no staining), + (less than 25% of tumoral cells stained), and ++ (more than 25% of tumoral cells stained).
Table 1 shows the clinicopathological results. Briefly, tumours from patients with BRCA1 mutations were mostly medullar carcinomas, had a high histological grade, and were oestrogen receptor negative.
All patients with BRCA1 germline mutations were in the “familial” group and belonged to high risk families. Three different BRCA1 germline mutations were found, namely: 1623del5 (two patients), 3450del4 (four patients), and 185delAG (one patient). All resulted in truncated proteins.
Table 2 lists the mutations found and their coding effects.
Staining was heterogeneous in intensity and localisation (cytoplasmic v nuclear), mainly as a result of the antibody and the antigen retrieval method used.
After autoclaving, nuclear staining was negative in tumoral cells from patients with and without BRCA1 mutations with the D-20 and K-18 polyclonal antibodies.
Twenty cases failed to show nuclear staining with the I-20 polyclonal antibody: 18 were from patients without BRCA1 mutations and corresponded to five familial and 13 sporadic breast tumours; the other two (cases 1 and 4) were from patients with BRCA1 germline mutations 1623del5 and 3450del4. Four tumours from patients carrying the same mutations (case 2 and cases 5, 6, and 7) showed intense nuclear staining with this same antibody.
After microwave pretreatment, 24 tumours did not show nuclear staining with the MS110 monoclonal antibody (fig 1); 21 were from patients without BRCA1 germline mutations and corresponded to 10 familial and 11 sporadic breast tumours; the other three (cases 1, 3, and 4) were from patients with BRCA1 germline mutations 1623del5, 185delAG, and 3450del4. The remaining four tumours, however, from patients with the 1623del5 (case 2) and 3450del4 (cases 5, 6, and 7) mutations, showed nuclear staining; hence, the presence or absence of nuclear staining was not related to the presence or absence of BRCA1 germline mutations (fig 2), or to the type of BRCA1 mutation present.
Cytoplasmic staining was positive in all 45 cases with the D-20 and I-20 polyclonal antibodies, in contrast to the staining pattern found with the MS110 monoclonal antibody, which was predominantly nuclear, with the exception of one sample (case 24) without BRCA1 mutations. The K-18 polyclonal antibody gave positive results for cytoplasmic staining in 10 patients (1, 3, and 7 all of whom had BRCA1 mutations). As with the nuclear staining, no correlation was found between staining and the presence or absence of BRCA1 germline mutations.
The cytoplasmic staining pattern was predominantly diffuse. A membrane staining pattern was also seen in 19 patients (patients 2 and 6 had BRCA1 mutations) when the D-20 antibody was used (fig 3); in addition, one patient (case 11) showed a granular cytoplasmic staining with the K-18 antibody (data not shown).
Results in non-tumoral cells present within the samples were similar to those observed in tumoral cells. No nuclear staining was seen with the D-20 and K-18 antibodies and only cytoplasmic staining was seen in these cases. We found cytoplasmic and nuclear staining in seven patients with the I-20 antibody, and two of these patients (cases 1 and 5) had BRCA1 germline mutations. Finally, with the MS110 antibody, non-tumoral cells showed a predominantly nuclear staining pattern in all patients (data not shown).
Tables 2 and 3 show the results of the immunohistochemical study. We found no correlation between BRCA1 staining and other prognostic factors, such as oestrogen receptor or axillary lymph node status. Only tumoral size (tumours ≥ 4 cm) and certain histological types (medullar carcinoma) appeared to correlate with the absence of BRCA1 staining, whereas most of the grade I tumours were positive.
In our study, we describe the use of immunohistochemistry on routinely processed, neutral formalin fixed and paraffin wax embedded tumours from 45 patients with breast carcinoma (23 familial, 22 sporadic).
The BRCA1 gene had been studied previously in all cases, and three different BRCA1 germline mutations (185delAG, 1623del5, and 3450del4) were found in seven patients from the familial group; all were frameshift mutations resulting in truncated proteins.
There is controversy regarding the size and localisation of the BRCA1 protein, mainly as a result of differences in fixation,15, 17 the antigen retrieval method used, and the specificity of anti-BRCA1 antibodies.27, 28 Using autoclaving and microwave antigen retrieval methods, we found that of all of the antibodies tested (D-20, I-20, K-18, and MS110), only MS110 (Ab-1) produced consistent results on routinely processed material.
Using the D-20 and K-18 antibodies, we found cytoplasmic staining only, the nucleus being constantly non-immunoreactive either in cancer or normal mammary gland cells in all samples tested. This agrees with data from a previous report29 in which only cytoplasmic staining was seen using polyclonal antibodies D-20, I-20, K-18, and C-20 on paraffin wax embedded samples. Our results differ from those of Jarvis,26 who found differences in nuclear staining of tumour cells with the D-20 antibody, the cytoplasm being positive in all sporadic breast cancers tested.
Using the C-terminal I-20 polyclonal antibody, we found no differences in staining between tumoral and non-tumoral mammary epithelial cells. Uniform cytoplasmic staining was seen in all samples with heterogeneous nuclear staining. Data have been published demonstrating I-20 false positive immunostaining using cell lines lacking the C-terminal portion of the BRCA1 protein19; furthermore, the I-20 antibody probably recognises proteins other than BRCA1,30 or products of alternative splicing of the BRCA1 gene.18
Although these polyclonal antibodies (D-20, I-20, and K-18) were valid for immunoprecipitation studies, their value for immunohistochemistry on frozen or paraffin wax embedded samples has been questioned.18
The MS110 antibody reacts with the N-terminal portion of the BRCA1 protein only after antigen retrieval by heating (microwave or autoclaving), producing an almost exclusively nuclear staining pattern in normal mammary cells.15, 20
Using the MS110 antibody and antigen retrieval with a microwave oven, we observed complete loss of nuclear staining in three of the seven familial BRCA1 associated breast cancers. Similar results were seen by Yoshikawa et al,19 who found a loss of nuclear signal in seven of the 19 BRCA1 associated breast carcinomas studied.
As expected, no signal was detected in the malignant cells in the only tumour containing the BRCA1 185delAG mutation, which results in the deletion of most of the protein, including the Ab-1 epitope. No nuclear signal was seen in tumour cells from patients carrying the 1623del5 and 3450del4 BRCA1 germline mutations, in agreement with previous reports in which the expression of BRCA1 mRNA in BRCA1 associated cancer was found to be low, regardless of the type of mutation,19, 31 because loss of the BRCA1 protein occurs irrespective of the position of the mutation in the BRCA1 gene.20
Some data from previous studies have shown that the BRCA1 protein is present in the cytoplasm. Splice variant isoforms that lack exon 11 along with the nuclear localisation signal are located exclusively in the cytoplasm.29, 32 However, we found no cytoplasmic staining with the MS110 antibody in the 45 breast cancers that we tested.
We found that different patients were carriers of the same truncating mutation: 1623del5 (patients 1 and 2) and 3450del4 (patients 4–7). Of particular interest was the fact that with the MS110 antibody negative nuclear staining was seen in patients 1 and 4 only, and staining was positive in the remainder of the tumours. The expression of BRCA1 mRNA is directly related to the number of wild-type alleles.33 The relatively high amounts of BRCA1 protein that we detected immunohistochemically in some of the tumours with truncated BRCA1 proteins, and the discrepancies between tumours carrying the same mutation, may result either from the retention of the wild-type allele or heterozygosity among cancer cells.19, 33 Results reported by Yoshikawa and colleagues19 support the idea that MS-110 could be useful in prescreening tumours for BRCA1 mutations, mainly because of the high detection rate (seven of nineteen) of alterations in the BRCA1 gene product in BRCA1 associated breast cancers. Our results (three of seven) are quite similar to those of Yoshikawa19 when only the familial BRCA1 associated breast cancers are compared. Applying these criteria, our apparent detection rate of BRCA1 mutations using the MS110 antibody is highest in familial (62.5%) and sporadic (50%) non-BRCA1 associated breast carcinomas. The presence or absence of BRCA1 germline mutations was objectively demonstrated in all patients after the study of the BRCA1 gene by PTT, CSGE, and direct sequencing of genomic DNA.
Taylor et al reported the absence of nuclear and cytoplasmic BRCA1 expression in 142 non-familial breast cancers studied by immunohistochemistry, and loss of nuclear BRCA1 expression in 19% of the cases, indicating that BRCA1 plays a role in sporadic cancers.20 Similar results have been reported in other immunohistochemical studies on sporadic, non-inherited breast cancer that used the MS110 (Ab-1) antibody, with a reduction in nuclear BRCA1 expression in 27%,19 20%,34 and 43.5%18 of the tumours tested.
A reduction of BRCA1 protein expression in sporadic carcinomas has been associated with high histological grade tumours,18 overexpression19 and loss34 of the c-erb-B-2 protein, and high proliferative phenotype, perhaps related to truncations at the N-terminal and C-terminal portions of the BRCA1 protein.26 We did not find a relation between the loss of nuclear staining and histological grade, tumour type, other clinicopathological data, or expression of oestrogen or progesterone receptors, p53, cathepsin D, c-erbB-2, and bcl-2 using immunohistochemistry (data not shown).
These data are consistent with the observation that BRCA1 mRNA values are decreased in sporadic breast cancers35 and in breast cancer cell lines such as MCF-7.33 Concentrations of the BRCA1 protein are also decreased in mammary tumours compared with matched normal breast tissue,36 implying multiple mechanisms of BRCA1 expression downregulation in these tumours. Other data suggest that the reduced expression of the BRCA1 protein might play an important role in mammary carcinogenesis in sporadic cancer, and that mechanisms other than mutation,19, 21 in particular LOH,29 might be involved in the reduced expression of the BRCA1 protein. Taken together, our data support the notion that the N-terminal specific MS110 antibody is not useful in prescreening BRCA1 mutations because it has a lower rate of detection in breast tumours from patients carrying a BRCA1 gene mutation than in tumours, both familial (65%) or sporadic (50%), from patients without BRCA1 germline mutations. This fact, together with the inconsistency in immunohistochemical results among patients carrying the same truncating BRCA1 mutation, points to the non-specificity of the MS110 antibody in the prescreening of BRCA1 associated mammary cancers.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.